This program provides an efficient way to explore state-of-the-art AML treatment options and decision-making algorithms. In this session, you will learn about the changes that have improved outcomes of allogeneic transplantation in patients with AML.
Frederick Appelbaum, M.D.
Clinical Research Director
Professor, Medical Oncology
University of Washington School of Medicine
- Discuss the use of allogeneic transplantation in patients with AML who fail induction therapy
- Cite cytogenetic abnormalities that affect outcomes in patients with AML receiving allogeneic transplantation
- Understand outcomes between matched related donor, matched unrelated donor, and cord blood in allogeneic transplantation of patients with AML
- Compare outcomes of allogeneic transplantation and chemotherapy in older patients with AML
The goal of this activity is to provide physicians and other health care professionals with information that impacts the treatment algorithms for AML and MDS, such as the role of risk stratification, the outcomes of chemotherapy and transplantation and the state of current clinical trials.
This activity is intended for hematologists/oncologists, transplant physicians and other health care professionals.
If you have any questions regarding this program, call Renee Ryan at (800) 526-7809 ext. 8430, or e-mail firstname.lastname@example.org.